In this review, we describe the currently accepted standard of care (SoC) treatment for AD and the most promising strategies for DMT under clinical development: (i) Cholinergic and dopaminergic system and Ca2+ signaling, and therapeutical interventions targeting (ii) Amyloid-β protein, (iii) Tau, (iv) inflammation, (v) Lipids and ApoE and (vi) Plasma fractions and Therapeutic plasma exchange. Here, APOE is linked to Alzheimer disease.